A Novel DNA-Based Antimicrobial Compound for Treating Infections Caused by Neisseria Gonorrhoeae and Neisseria Meningitidis

UA ID Technology #ua18-253

Title: A Novel DNA-based Antimicrobial Compound for Treating Infections Caused by Neisseria Gonorrhoeae and Neisseria Meningitidis

Invention: This invention is an antimicrobial compound made of nucleic acid that can treat diseases caused by the pathogens Neisseria Gonorrhoeae (Ngo) and Neisseria Meningitidis (Nme).

Background: Ngo is a common cause of infection globally, and when left untreated, it can cause pelvic inflammatory disease, infertility issues and increased susceptibility to HIV. Many Neisseria strains are antibiotic resistant and are very hard to clear from the system. Current standards require dual therapy in order to try to combat the infection and reduce further development of antibiotic resistance. Therefore there is a large need for new therapeutic options to fight Neisseria infections.

Applications:
- Therapeutic option for treating bacterial disease
- Treatment against Nme and Ngo pathogens

Advantages:
- Provides several potential models of delivery
- Ease of delivery
- Dual functionality
- Highly effective

Licensing Manager:
Tod McCauley

The University of Arizona, Tucson, Arizona
Todm@tla.arizona.edu
(520) 626-7916

Inventors

Maira Goytia
Visiting Research Scientist, Immunology

Ann Jerse
Professor, Microbiology

Dustin Higashi
Technician

Won Jong Kim
Research Administrator, BIO5 Institute

Magdalene So
Professor, Immunobiology